Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

To compare the pharmacokinetic characteristic of LBEC0101 25mg with the active comparator, Enbrel® 25 mg.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: LG Life Sciences
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Healthy males, 20 to 45 years of age the moment of screening

• Body mass index is between 18.0 and 30.0 kg/m

Exclusion Criteria:

• The tuberculosis patient or latent tuberculosis patient

• Hypersensitivity response to the test and comparator drugs